Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

EMD Serono Research & Development Institute, Inc. · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
immune-checkpoint-inhibitorimmunotherapy
metastatic or locally advanced unresectable solid tumors, atr inhibitor, atm inhibitor, immunotherapy, tuvusertib (m1774), lartesertib (m4076), avelumab, dna damage response inhibitor, immune checkpoint inhibitor, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 889901
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.